75522
document
[ Prevention of migraine with flunarizine and acetylsalicylic acid . A double-blind study ] . UNLABELLED 30 children between 7 and 17 years suffering from at least 2 attacks/month of common or classical migraine since more than 1 year were studied . After clinical exclusion of symptomatic headache 4 weeks were documented by means of a migraine diary . Prophylaxis with Calcium entry blocker Flunarizine ( Sibelium ) or Thromboxane A inhibitor Acetylsalicylic acid ( ASS ) was carried out in a double blind design for 3 months . Medication was given as one dosage in the evening : 2-5 mg/kg KG ASS or 5-10 mg Flunarizine . Documented attack frequency and duration were controlled at monthly physical examinations . Final results showed no differences in significant reduction of attack frequency or symptoms between both different therapeutic principals . 72.4 % ( ASS 73.3 % ; Flunarizine 71.4 % ) of patients were attack-free or had at least a 50 % reduction . Migraine frequency of initially 7-8 was reduced to 1-2 attacks/month . Duration remained constant in both groups ( 1-3 h ) . Side effects were slight body weight gain or abdominal pain after intake , prophylaxis had not to be interrupted therefore . Longtime prognosis is not yet possible because the time of observation is too short so far . CONCLUSION Both substances are definitely useful and have few side effects in childhood migraine . If the response to one is insufficient the other substance should be tried .
75523
Intervention_Pharmacological
flunarizine
75524
Intervention_Pharmacological
acetylsalicylic acid
75525
Intervention_Pharmacological
blocker Flunarizine ( Sibelium )
75526
Intervention_Pharmacological
Acetylsalicylic acid ( ASS )
75527
Intervention_Pharmacological
ASS
75528
Intervention_Pharmacological
Flunarizine
75529
Intervention_Pharmacological
Flunarizine
75530
Outcome_Mental
migraine
75531
Outcome_Physical
attack frequency and duration
75532
Outcome_Physical
reduction of attack frequency or symptoms
75533
Outcome_Other
Migraine frequency
75534
Outcome_Other
Duration
75535
Outcome_Adverse-effects
slight body weight gain
75536
Outcome_Adverse-effects
abdominal pain
75537
Participant_Condition
migraine
75538
Participant_Sample-size
30
75539
Participant_Age
children between 7 and 17
75540
Participant_Condition
common or classical migraine
75541
Participant_Condition
childhood migraine .